Teva Pharma (TEVA) Misses Q4 EPS by 1c, FY Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Teva Pharma (TEVA) PT Lowered to $20 at RBC Capital
February 14, 2019 6:50 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Teva Pharma (NYSE: TEVA) to $20.00 (from $22.00) while maintaining a Sector Perform rating.
... More